This inventor holds 6 USPTO granted patents and 3 published patent applications and 3 EPO patents. Top assignees: Baxalta Gmbh, Geneuro Sa, Baxter Healthcare Sa. Active years: 2015-2020.
Company Filing History:
2 out of 153 
2 out of 9 
1 out of 1,200 
Years Active: 2015-2020
Title: Patrick Küry: Innovator in Neurological Treatments
Introduction
Patrick Küry is a prominent inventor based in Düsseldorf, Germany. He has made significant contributions to the field of neurology, particularly in the development of innovative compounds for treating demyelinating diseases. With a total of 6 patents, his work focuses on enhancing the repair mechanisms of the nervous system.
Latest Patents
Küry's latest patents include groundbreaking inventions aimed at addressing the remyelination blockade in diseases associated with the expression of the HERV-W envelope protein. One notable patent involves compounds and compositions designed to prevent and treat this detrimental mechanism, which hinders the adult nervous system's ability to repair myelin. Another significant patent highlights the use of polyclonal IgG to stimulate remyelination of peripheral nerves. This invention provides methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, including conditions such as peripheral nerve trauma and toxin-induced neuropathies.
Career Highlights
Throughout his career, Patrick Küry has worked with notable companies such as Baxalta GmbH and GeNeuro SA. His experience in these organizations has allowed him to advance his research and contribute to the development of effective treatments for neurological disorders.
Collaborations
Küry has collaborated with esteemed colleagues, including Hans-Peter Hartung and Nevena Tzekova. These partnerships have further enriched his research and innovation efforts in the field of neurology.
Conclusion
Patrick Küry's contributions to neurological treatments through his innovative patents and collaborations underscore his importance in the field. His work continues to pave the way for advancements in the treatment of demyelinating diseases.